OK-432 sclerotherapy in head and neck lymphangiomas: long-term follow-up result.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 19130974.
- Also identified by DOI 10.1016/j.otohns.2008.10.026.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nonsurgical treatments, such as sclerotherapy have been attempted for head and neck lymphagiomas. Of the available sclerosing agents, picibanil has shown satisfactory short-term treatment results in many studies, but no study has presented long-term treatment results. Accordingly, in the present study, the authors retrospectively reviewed the long-term treatment results of picibanil sclerotherapy. Fifty-five lymphangioma patients who underwent picibanil sclerotherapy were enrolled. Data about initial and long-term response, recurrence, and excision rate were collected. Initial response rates were 83.5 percent and long-term response rates were 76.3 percent. Initial and the long-term response rate were equally good for lymphangioma.
Medical subject headings
- Head and Neck Neoplasms
- Lymphangioma
- Picibanil
- Sclerosing Solutions
- Sclerotherapy